tiprankstipranks
Advertisement
Advertisement

XENE Stock Latest News

Xenon Pharmaceuticals Signals Strong Momentum In Earnings
Company AnnouncementsXenon Pharmaceuticals Signals Strong Momentum In Earnings
4d ago
XENE
Xenon Pharmaceuticals price target raised to $80 from $77 at JPMorgan
PremiumThe Fly
Xenon Pharmaceuticals price target raised to $80 from $77 at JPMorgan
12d ago
XENE
Xenon Pharmaceuticals price target raised to $69 from $68 at Wells Fargo
PremiumThe Fly
Xenon Pharmaceuticals price target raised to $69 from $68 at Wells Fargo
14d ago
PRAX
XENE
Xenon Pharmaceuticals Maps Path After Standout XTOL-2
PremiumCompany Announcements
Xenon Pharmaceuticals Maps Path After Standout XTOL-2
15d ago
XENE
Xenon Pharmaceuticals price target lowered to $78 from $80 at Needham
PremiumThe Fly
Xenon Pharmaceuticals price target lowered to $78 from $80 at Needham
16d ago
XENE
Analyst Reaffirms Buy on Xenon, Citing Blockbuster Potential for Lead Epilepsy Candidate and Upside from Pipeline Programs
PremiumRatingsAnalyst Reaffirms Buy on Xenon, Citing Blockbuster Potential for Lead Epilepsy Candidate and Upside from Pipeline Programs
17d ago
XENE
Xenon Highlights Positive Phase 3 Azetukalner Seizure Data
Premium
Company Announcements
Xenon Highlights Positive Phase 3 Azetukalner Seizure Data
17d ago
8K
XENE
Xenon Pharmaceuticals reports Q1 EPS ($1.17), consensus ($1.20)
Premium
The Fly
Xenon Pharmaceuticals reports Q1 EPS ($1.17), consensus ($1.20)
17d ago
XENE
XENE Upcoming Earnings Report: What to Expect?
PremiumPre-Earnings
XENE Upcoming Earnings Report: What to Expect?
19d ago
XENE
Xenon’s Azetukalner: Rapid, Durable Efficacy and Once‑Daily Convenience Underpin Buy Rating and Preferred Second‑Line Epilepsy Positioning
PremiumRatings
Xenon’s Azetukalner: Rapid, Durable Efficacy and Once‑Daily Convenience Underpin Buy Rating and Preferred Second‑Line Epilepsy Positioning
1M ago
XENE
Xenon Pharmaceuticals presents data from Phase 3 X-TOLE2 study
PremiumThe Fly
Xenon Pharmaceuticals presents data from Phase 3 X-TOLE2 study
1M ago
XENE
Xenon to Spotlight Neurology Pipeline at Series of 2026 Investor Conferences
PremiumCompany Announcements
Xenon to Spotlight Neurology Pipeline at Series of 2026 Investor Conferences
1M ago
XENE
Xenon Expands 2025 Inducement Equity Incentive Plan
PremiumCompany AnnouncementsXenon Expands 2025 Inducement Equity Incentive Plan
1M ago
8K
XENE
Xenon to Unveil Phase 3 Azetukalner Data and Pipeline Advances at 2026 AAN Meeting
Premium
Company Announcements
Xenon to Unveil Phase 3 Azetukalner Data and Pipeline Advances at 2026 AAN Meeting
2M ago
XENE
Xenon Pharmaceuticals price target lowered to $63 from $64 at Wedbush
Premium
The Fly
Xenon Pharmaceuticals price target lowered to $63 from $64 at Wedbush
2M ago
XENE
Xenon Sets Date for 2026 Annual Shareholder Meeting
PremiumCompany Announcements
Xenon Sets Date for 2026 Annual Shareholder Meeting
2M ago
8K
XENE
Xenon’s X-TOLE2 Trial Completion Puts XEN1101 in Focus for Epilepsy Investors
PremiumCompany Announcements
Xenon’s X-TOLE2 Trial Completion Puts XEN1101 in Focus for Epilepsy Investors
2M ago
XENE
Xenon Strengthens Balance Sheet With Major Equity Offering
PremiumCompany Announcements
Xenon Strengthens Balance Sheet With Major Equity Offering
2M ago
8K
XENE
Xenon Pharmaceuticals 10.5M share Spot Secondary priced at $57.00
PremiumThe Fly
Xenon Pharmaceuticals 10.5M share Spot Secondary priced at $57.00
2M ago
XENE
Xenon Raises $650 Million in Upsized U.S. Equity Offering
PremiumCompany AnnouncementsXenon Raises $650 Million in Upsized U.S. Equity Offering
2M ago
XENE
Xenon Pharmaceuticals: Buy Rating Backed by Superior X-TOLE2 Phase 3 Results and Commercial Upside for Azetukalner in Focal Epilepsy
Premium
Ratings
Xenon Pharmaceuticals: Buy Rating Backed by Superior X-TOLE2 Phase 3 Results and Commercial Upside for Azetukalner in Focal Epilepsy
2M ago
XENE
Xenon Pharmaceuticals price target raised to $64 from $47 at Wedbush
Premium
The Fly
Xenon Pharmaceuticals price target raised to $64 from $47 at Wedbush
3M ago
XENE

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >